PET/CT and renal pathology: A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease

Katherine Zukotynski, Aaron Lewis, Kevin O'Regan, Heather Jacene, Christopher Sakellis, Samuel Almodovar, David Israel

Research output: Contribution to journalReview article

Abstract

OBJECTIVE. PET/CT with 18F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer uptake and the key anatomic features of lymphoma, leukemia, and metastatic disease involving the kidney on FDG PET/CT. CONCLUSION. Close attention to both the FDG PET and CT portions of an FDG PET/CT study is essential to evaluate the kidneys in oncology patients.

Original languageEnglish (US)
Pages (from-to)W168-W174
JournalAmerican Journal of Roentgenology
Volume199
Issue number2
DOIs
StatePublished - Aug 1 2012

Keywords

  • FDG PET/CT
  • Oncology
  • Renal pathology

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'PET/CT and renal pathology: A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease'. Together they form a unique fingerprint.

  • Cite this

    Zukotynski, K., Lewis, A., O'Regan, K., Jacene, H., Sakellis, C., Almodovar, S., & Israel, D. (2012). PET/CT and renal pathology: A blind spot for radiologists? Part 2 - Lymphoma, leukemia, and metastatic disease. American Journal of Roentgenology, 199(2), W168-W174. https://doi.org/10.2214/AJR.11.7923